Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Completion of Merger Between Vivalis and Intercell to Form Valneva

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Creating a European biotech leader in vaccines and antibodies.

Valneva SE (Valneva) has announced the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in its field.

Valneva ordinary shares (ISIN FR0004056851) start trading on the regulated market of NYSE Euronext in Paris under the ticker symbol “VLA.PA” and on the Prime Market segment of the Vienna Stock Exchange under the ticker symbol “VLA”.

Valneva preferred shares (ISIN FR0011472943) will start trading on the regulated market of NYSE Euronext in Paris under ticker symbol “VLApr.PA” and on the unregulated Third Market Segment of the Vienna Stock Exchange under the ticker symbol “VLAP”.

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva, commented: “Today is a major milestone for our new company. Valneva combines the strengths and capabilities of Vivalis and Intercell in antibody discovery and vaccine development and commercialization. We have a clear growth strategy to build a sustainable business by growing revenues through marketed products as well as through existing and future partnerships, and to invest into vaccines development and antibody discovery. We believe this value proposition will generate substantial rewards for our shareholders.”

Valneva operates across the whole biopharmaceutical value chain with innovative technology platforms, discovery and development capabilities, manufacturing and commercialization expertise.

Valneva generates revenue from diversified sources including its marketed product as well as current and new commercial partnerships.

Valneva has a broad portfolio of product candidates (in-house/partnered) including a pandemic Influenza vaccine in Phase III, a Pseudomonas vaccine in Phase II/III and a Tuberculosis vaccine in Phase II.

It has also a portfolio of technology platforms that are becoming widely adopted by the biopharmaceutical industry at large. These include the validated and commercialized technology platforms EB66® cell line for human and veterinary product development, VIVA|Screen™ antibody discovery platform and IC31® novel adjuvant.

Intended Rights Issue of an envisaged amount of EUR 40 million
As announced on December 16th 2012, Valneva plans to launch, subject to market conditions and to the approval from the French Autorité des marchés financiers on the Prospectus which will be prepared for this purpose, rights issue of an envisaged amount of EUR 40 million.

Valneva has received the following commitments with respect to the intended rights issue, and therefore already secured EUR 40 million:

• The FSI has undertaken to participate to the rights issue for a maximum amount of EUR 25 million (within the limit of 62.5% of the proceeds of the issue) on the basis of irrevocable entitlement (à titre irréductible) and on the basis of entitlement subject to reduction (à titre réductible);

• Groupe Grimaud and Unigrains (one of Groupe Grimaud’s long-term shareholders) have irrevocably undertaken to participate in aggregate to the rights issue for EUR 5 million and on the basis of entitlement subject to reduction (à titre réductible);

• Two banks have committed to underwrite EUR 10 million under market-standard terms and conditions.

Goldman Sachs International and Société Générale Corporate and Investment Banking are acting as advisors on the merger.

Credit Agricole Corporate and Investment Bank and Société Générale Corporate and Investment Banking are acting as Joint Lead Managers and Joint Bookrunners for the rights issue.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vivalis and Intercell Merge to form Valneva
Completion of merger process creates a European biotech leader in vaccines and antibodies.
Wednesday, May 29, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!